JavaScript Disabled

This site requires JavaScript Enabled to function properly. Please enable JavaScript or use a different browser that has JavaScript enabled.

Buying For Victoria
Skip to main content

Display Tender HPVITS2019-058.003 

This page displays the details of a tender.

HPVITS2019-058.003 Pharmaceutical Products and IV Fluids Supplementary Tender 003
Issued By HealthShare Victoria
Advanced Tender Notice
Status:
Closed
Number:
HPVITS2019-058.003
Contract Number
HPVITS2019-058
Estimated Advertising Date:
7 April 2021 02:00 PM
UNSPSC
Carmustine - (6%)
Desflurane - (6%)
Vancomycin - (6%)
Oseltamivir - (8%)
Imatinib - (10%)
Cabazitaxel - (6%)
Arsenic trioxide - (6%)
Bevacizumab - (6%)
Bortezomib - (6%)
Frusemide or furosemide - (6%)
Deferasirox - (10%)
Daptomycin - (6%)
Moxifloxacin - (6%)
Nitroprusside - (6%)
Methylprednisolone sodium succinate - (6%)

Enquiries 

Contacts

Description 

Agency: HealthShare Victoria

Type of work: Goods & Services

Type: Request for Tender

Title: HPVITS2019-058.003 – Pharmaceutical Products and IV Fluids Supplementary 003

RFx Number:  HPVITS2019-058.003

Description:

Notice of upcoming tender:

HPVITS2019-058.003 – Pharmaceutical Products and IV Fluids Supplementary 003

Scope: 

Subcategory number Subcategory name

517.01

Arsenic trioxide 10mg/10mL injection, ampoule/vial,10mL

83001.01

Bevacizumab 100mg/4mL injection, ampoule/vial, 4mL

83001.02

Bevacizumab 400mg/16mL injection, ampoule/vial, 16mL

518.01

Bortezomib injection, ampoule/vial

519.01

Cabazitaxel 60mg injection, ampoule/vial

527.01

Carmustine 100mg injection, ampoule/vial

520.01

Daptomycin 350mg injection, ampoule/vial

520.02

Daptomycin 500mg injection, ampoule/vial

521.01

Deferasirox 90mg tablet/capsule 30

521.02

Deferasirox 180mg tablet/capsule 30

521.03

Deferasirox 360mg tablet/capsule 30

522.01

Desflurane 1mL/1mL or 1g/1g Inhalation solution, bottle 250mL

197.03

Furosemide (Frusemide) 20mg/2mL injection, ampoule/vial, 2mL

523.01

Imatinib 100mg tablet/capsule 30 (GIST indication)

523.02

Imatinib 100mg tablet/capsule 30 (non-GIST indication)

523.03

Imatinib 400mg tablet/capsule 60 (GIST indication)

523.04

Imatinib 400mg tablet/capsule 60 (non-GIST indication)

524.01

Methylprednisolone (sodium succinate) 500mg injection, ampoule/vial

524.02

Methylprednisolone (sodium succinate) 1g injection, ampoule/vial

325.02

Moxifloxacin 400mg tablet/capsule 5

525.01

Oseltamivir 30mg capsule 10

525.02

Oseltamivir 45mg capsule 10

525.03

Oseltamivir 75mg capsule 10

526.01

Sodium nitroprusside 50mg/2mL injection, ampoule/vial, 2mL

499.04

Vancomycin 500mg injection, ampoule/vial

Market Release Date: 01 March 2021

All enquiries regarding this supplementary tender prior to the market release date should be directed to r.luong@healthsharevic.org.au or (03)99473933 . Once the tender has been released, please direct all correspondence through the HSV Procurement Portal.